Nuvama Fund Acquires 8.4% Stake in Sudeep Pharma
Nuvama Crossover Opportunities Fund, along with its Persons Acting in Concert (PACs), has disclosed a substantial acquisition of shares in Sudeep Pharma Limited. The acquisition, which occurred through a combination of preferential allotment (pre-IPO) and open market purchases (IPO), resulted in the fund holding 94,51,295 shares, representing 8.4% of the total share capital. The acquisition process spanned multiple dates, starting from July 9, 2024, and concluding with the IPO allotment date of November 27, 2025. This disclosure is made under SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011. Concurrently, the fund has also disclosed a sale of 26,68,118 shares, reducing its holding to 67,83,177 shares, or 6.0% of the total share capital.
Key Highlights
- Nuvama Crossover Opportunities Fund acquired 8.4% stake in Sudeep Pharma.
- Acquisition involved preferential allotment and open market purchases.
- The fund has since sold a portion of its stake, now holding 6.0%.
- Disclosure made under SEBI (Substantial Acquisition of Shares & Takeovers) Regulations.
- Acquisition and sale occurred over multiple dates around the IPO.
Price Impact
More from SUDEEPPHRM